Hematology

A recent comparison of health-related quality of life scores also favored ide-cel over belantamab mafodotin treatment.

Marker will initiate a company-sponsored study after an initial trial at Baylor College of Medicine showed positive safety data.

Experts discuss providing supportive care to patients receiving CAR T-cell therapy.

CT103A, a fully human BCMA-directed CAR T-cell therapy, demonstrated deepening efficacy with an acceptable toxicity profile, according to updated data from the phase 1/2 FUMANBA-1 trial.

Among the programs involved are therapies for multiple myeloma and B-cell malignancies.

Pre-clinical data showed that EZ-T cells have increased anti-tumor activity compared with traditional iPSC-derived T-cells.

The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed work that needs to be done to support the use of CAR T therapy.

Review top news and interview highlights from the week ending August 5, 2022.

Topline results are expected to be announced by the fourth quarter of 2022.

Incidences of graft versus host disease will be a focal point of the study.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

UCART2022 is an allogeneic therapy that targets both CD20 and CD22.

Omidubicel demonstrated neutrophil engraftment a median of 10 days faster than standard UCBT.

Milan Zdravkovic, MD, PhD, chief medical officer of SNIPR Biome, discussed the company’s ongoing research on targeting E Coli in the blood with CRISPR-based medication.

Experts shared opinions about the future of gene therapy in sickle cell and other rare diseases.

Review top news and interview highlights from the week ending July 29, 2022.

The associate professor at Fred Hutch Cancer Center discussed next steps with the clinical trial being conducted Fred Hutch Cancer Center.

The company announced successful neutrophil and platelet engraftment for the first patient dosed.

The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed new CAR T-cell therapies being investigated for hematologic malignancies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

All 3 patients remained progression-free at more than 1 year post-treatment.

Nilanjan Ghosh, MD, PhD, discussed the impact of liso-cel's approval.

The director of the Pediatric Hemophilia and Coagulation Disorders Program at CS Mott Children’s Hospital discussed current studies evaluating gene therapies in hemophilia.

Most patients treated with FLT180a had elevated FIX levels over 2 years after treatment.

The chief of the oncology branch of the Center for Biologics Evaluation and Research at the FDA discussed how academia and industry can work best with regulatory agencies.